Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia

Kidney International

Volumn 64, Issue 5, 2003, Pages 1653-1661

  Cozzolino, Mario ^b   Staniforth, Mark E ^b   Liapis, Helen ^b   Finch, Jane ^b   Burke, Steven K ^b   Dusso, Adriana S ^b   Slatopolsky, Eduardo ^a  

^a Renal Division   (United States)

^b NONE

Author keywords

Phosphate; Renal failure; Vascular calcification

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CELL MARKER; CHOLESTEROL; CREATININE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CALCIFICATION; ARTICLE; CALCIFICATION; CAPILLARY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIET; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; EXPERIMENT; FEEDING; FEMALE; HEART CALCIFICATION; HYPERPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CALCIFICATION; KIDNEY FAILURE; KIDNEY FUNCTION; MORTALITY; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RAT; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; UREMIA;

EID: 0142187235     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00284.x     Document Type: Article

References (27)

1. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
2. SCHWARTZ U, BUZZELLO M, RITZ E, et al: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218-223, 2000
3. LONDON GM, PANNIER B, MARCHAIS SJ, GUERIN AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 11: 778-783, 2000
4. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701, 2002
5. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
6. COZZOLINO M, DUSSO A, SLATOPOLSKY E: Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12:2511-2516, 2001
7. SLATOPOLSKY E, BROWN A, DUSSO A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37:S54-S57, 2001
8. MASSRY SG: The toxic effects of parathyroid hormone in uremia. Semin Nephrol 3:306-328, 1983
9. WALLIN R, WAJIH N, GREENWOOD GT, SANE DC: Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 21:274-301, 2001
10. SCHINKE T, MCKEE MD, KIVIRANTA R, KARSENTY G: Molecular mechanisms of arterial calcification. Ann Med 30:538-541, 1998
11. BOSTROM K: Insight into the mechanisms of vascular calcification. Am J Cardiol 88(Suppl 1):20-22. 2001
12. PROUDFOOT D, SHANAHAN CM: Biology of calcification in vascular cells: Intima versus media. Herz 26:245-251, 2001
13. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:e10-e17, 2000
14. CHEN N, O'NEILL K, DUAN D, MOE S: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62:1724-1731, 2002
15. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
16. CANNATA-ANDIA JB: Reconsidering the importance of long-term low-level aluminum exposure in renal failure patients. Semin Dial 14:5-7, 2001
17. KAUSZ AT, ANTONSEN JE, HERCZ G, et al: Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 34:688-693, 1999
18. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000
19. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
20. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29:641-649, 1997
21. CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 14:2907-2914, 1999
22. BLEYER AJ, BURKE SK, DILLON M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
23. SLATOPOLSKY EA, BURKE SK, DILLON MA: RenaGel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299-307, 1999
24. COZZOLINO M, DUSSO A, LIAPIS H, et al: Effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308, 2002
25. QUNIBI W, NOLAN C, AYUS J: Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int 62(Suppl 82):S73-S80, 2002
26. PROUDFOOT D, DAVIES J, SKEPPER J, et al: Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 106:3044-3050, 2002
27. PARHAMI F, BASSERI B, HWANG J, et al: High-density lipoprotein regulates calcification of vascular cells. Circ Res 91:570-576, 2002